Adaptive Biotechnologies CorpADPTEarnings & Financial Report
ExpreS2ion Biotechnologies is a Danish biotechnology company specialised in the development of new vaccines and immunotherapy products based in Hørsholm, Denmark and listed on the Nasdaq First North Growth Market Sweden.
ADPT Q1 FY2026 Key Financial Metrics
Revenue
$70.9M
Gross Profit
$52.2M
Operating Profit
$-19.2M
Net Profit
$3.4M
Gross Margin
73.6%
Operating Margin
-27.1%
Net Margin
4.7%
YoY Growth
35.1%
Adaptive Biotechnologies Corp Q1 FY2026 Financial Summary
Adaptive Biotechnologies Corp reported revenue of $70.9M (up 35.1% YoY) for Q1 FY2026, with a net profit of $3.4M (4.7% margin). Cost of goods sold was $18.7M, operating expenses totaled $71.4M.
Key Financial Metrics
| Total Revenue | $70.9M |
|---|---|
| Net Profit | $3.4M |
| Gross Margin | 73.6% |
| Operating Margin | -27.1% |
| Report Period | Q1 FY2026 |
Adaptive Biotechnologies Corp Annual Revenue by Year
Adaptive Biotechnologies Corp annual revenue history includes year-by-year totals (for example, 2025 revenue was $277.0M).
Adaptive Biotechnologies Corp Quarterly Revenue & Net Profit History
Adaptive Biotechnologies Corp results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $70.9M | +35.1% | $3.4M | 4.7% |
| Q4 FY2025 | $71.7M | +51.0% | $-13.6M | -18.9% |
| Q3 FY2025 | $94.0M | +102.4% | $9.5M | 10.2% |
| Q2 FY2025 | $58.9M | +36.3% | $-25.6M | -43.5% |
| Q1 FY2025 | $52.4M | +25.2% | $-29.9M | -56.9% |
| Q4 FY2024 | $47.5M | +3.7% | $-33.7M | -71.0% |
| Q3 FY2024 | $46.4M | +22.5% | $-32.1M | -69.1% |
| Q2 FY2024 | $43.2M | -11.7% | $-46.2M | -107.0% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $43.2M | $46.4M | $47.5M | $52.4M | $58.9M | $94.0M | $71.7M | $70.9M |
| YoY Growth | -11.7% | 22.5% | 3.7% | 25.2% | 36.3% | 102.4% | 51.0% | 35.1% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $584.9M | $558.5M | $539.4M | $510.9M | $496.6M | $490.6M | $512.7M | $505.9M |
| Liabilities | $343.4M | $334.9M | $336.9M | $320.6M | $317.1M | $286.4M | $287.7M | $281.7M |
| Equity | $241.6M | $223.8M | $202.7M | $190.4M | $179.7M | $204.4M | $218.8M | N/A |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-17.3M | $-27.1M | $-12.5M | $-28.5M | $-12.4M | $-7.1M | $2.1M |